Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Activation of Peripheral Opioid Kappa1 Receptor Prevents Cardiac Reperfusion Injury

S. V. Popov, A. V. Mukhomedzyanov, S. Y. Tsibulnikov, I. Khaliuli, P. R. Oeltgen, N. R. Prasad, L. N. Maslov

. 2021 ; 70 (4) : 523-531. [pub] 20210601

Jazyk angličtina Země Česko

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22007907

The role of opioid kappa1 and kappa2 receptors in reperfusion cardiac injury was studied. Male Wistar rats were subjected to a 45-min coronary artery occlusion followed by a 120-min reperfusion. Opioid kappa receptor agonists were administered intravenously 5 min before the onset of reperfusion, while opioid receptor antagonists were given 10 min before reperfusion. The average value of the infarct size/area at risk (IS/AAR) ratio was 43 - 48% in untreated rats. Administration of the opioid kappa1 receptor agonist (-)-U-50,488 (1 mg/kg) limited the IS/AAR ratio by 42%. Administration of the opioid kappa receptor agonist ICI 199,441 (0.1 mg/kg) limited the IS/AAR ratio by 41%. The non-selective opioid kappa receptor agonist (+)-U-50,488 (1 mg/kg) with low affinity for opioid kappa receptor, the peripherally acting opioid kappa2 receptor agonist ICI 204,448 (4 mg/kg) and the selective opioid ?2 receptor agonist GR89696 (0.1 mg/kg) had no effect on the IS/AAR ratio. Pretreatment with naltrexone, the peripherally acting opioid receptor antagonist naloxone methiodide, or the selective opioid kappa2 receptor antagonist nor-binaltorphimine completely abolished the infarct-reducing effect of (-)-U-50,488 and ICI 199,441. Pretreatment with the selective opioid ? receptor antagonist TIPP[psi] and the selective opioid μ receptor antagonist CTAP did not alter the infarct reducing effect of (-)-U-50,488 and ICI 199,441. Our study is the first to demonstrate the following: (a) the activation of opioid kappa2 receptor has no effect on cardiac tolerance to reperfusion; (b) peripheral opioid kappa1 receptor stimulation prevents reperfusion cardiac injury; (c) ICI 199,441 administration resulted in an infarct-reducing effect at reperfusion; (e) bradycardia induced by opioid kappa receptor antagonists is not dependent on the occupancy of opioid kappa receptor.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22007907
003      
CZ-PrNML
005      
20220323102117.0
007      
ta
008      
220309s2021 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934646 $2 doi
035    __
$a (PubMed)34062075
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Popov, S. V. $u Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, the Russian Academy of Sciences, Tomsk, Russia
245    10
$a Activation of Peripheral Opioid Kappa1 Receptor Prevents Cardiac Reperfusion Injury / $c S. V. Popov, A. V. Mukhomedzyanov, S. Y. Tsibulnikov, I. Khaliuli, P. R. Oeltgen, N. R. Prasad, L. N. Maslov
504    __
$a Literatura
520    9_
$a The role of opioid kappa1 and kappa2 receptors in reperfusion cardiac injury was studied. Male Wistar rats were subjected to a 45-min coronary artery occlusion followed by a 120-min reperfusion. Opioid kappa receptor agonists were administered intravenously 5 min before the onset of reperfusion, while opioid receptor antagonists were given 10 min before reperfusion. The average value of the infarct size/area at risk (IS/AAR) ratio was 43 - 48% in untreated rats. Administration of the opioid kappa1 receptor agonist (-)-U-50,488 (1 mg/kg) limited the IS/AAR ratio by 42%. Administration of the opioid kappa receptor agonist ICI 199,441 (0.1 mg/kg) limited the IS/AAR ratio by 41%. The non-selective opioid kappa receptor agonist (+)-U-50,488 (1 mg/kg) with low affinity for opioid kappa receptor, the peripherally acting opioid kappa2 receptor agonist ICI 204,448 (4 mg/kg) and the selective opioid ?2 receptor agonist GR89696 (0.1 mg/kg) had no effect on the IS/AAR ratio. Pretreatment with naltrexone, the peripherally acting opioid receptor antagonist naloxone methiodide, or the selective opioid kappa2 receptor antagonist nor-binaltorphimine completely abolished the infarct-reducing effect of (-)-U-50,488 and ICI 199,441. Pretreatment with the selective opioid ? receptor antagonist TIPP[psi] and the selective opioid μ receptor antagonist CTAP did not alter the infarct reducing effect of (-)-U-50,488 and ICI 199,441. Our study is the first to demonstrate the following: (a) the activation of opioid kappa2 receptor has no effect on cardiac tolerance to reperfusion; (b) peripheral opioid kappa1 receptor stimulation prevents reperfusion cardiac injury; (c) ICI 199,441 administration resulted in an infarct-reducing effect at reperfusion; (e) bradycardia induced by opioid kappa receptor antagonists is not dependent on the occupancy of opioid kappa receptor.
650    _2
$a 3,4-dichlor-N-methyl-N-(2-(1-pyrrolidinyl)-cyklohexyl)-benzenacetamid, (trans)-isomer $x aplikace a dávkování $x toxicita $7 D019900
650    _2
$a intravenózní podání $7 D061605
650    _2
$a opioidní analgetika $x aplikace a dávkování $x toxicita $7 D000701
650    _2
$a zvířata $7 D000818
650    _2
$a srdeční arytmie $x chemicky indukované $x patofyziologie $7 D001145
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infarkt myokardu $x metabolismus $x patologie $x prevence a kontrola $7 D009203
650    _2
$a reperfuzní poškození myokardu $x metabolismus $x patologie $x prevence a kontrola $7 D015428
650    _2
$a kardiomyocyty $x účinky léků $x metabolismus $x patologie $7 D032383
650    _2
$a narkotika - antagonisté $x aplikace a dávkování $7 D009292
650    _2
$a piperaziny $x aplikace a dávkování $7 D010879
650    _2
$a pyrrolidiny $x aplikace a dávkování $x toxicita $7 D011759
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory opiátové kappa $x agonisté $x metabolismus $7 D017473
650    _2
$a signální transdukce $7 D015398
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mukhomedzyanov, A. V. $u Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, the Russian Academy of Sciences, Tomsk, Russia
700    1_
$a Tsibulnikov, S. Y. $u Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, the Russian Academy of Sciences, Tomsk, Russia
700    1_
$a Khaliuli, I. $u School of Clinical Sciences, University of Bristol, Bristol Royal Infirmary, Bristol, United Kingdom
700    1_
$a Oeltgen, P. R. $u Department of Pathology, University of Kentucky College of Medicine, Lexington, USA
700    1_
$a Prasad, N. R. $u Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamilnadu, India
700    1_
$a Maslov, L. N. $u Laboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, the Russian Academy of Sciences, Tomsk, Russia
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, č. 4 (2021), s. 523-531
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34062075 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20220309 $b ABA008
991    __
$a 20220323102112 $b ABA008
999    __
$a ok $b bmc $g 1773037 $s 1159100
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 70 $c 4 $d 523-531 $e 20210601 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20220309

Najít záznam

Citační ukazatele

Možnosti archivace